Clinical trial
Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by…
NCT00149032 · Hadassah Medical Organization, Other · Withdrawn
Key facts
| NCT number | NCT00149032 |
|---|---|
| Title | Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host |
| Official title | Treatment of Patients With Resistant Cancer/ Post Allogeneic Stem Cell Transplantation With Donor Lymphocytes Sensitized by Antigens Expressed by the Host |
| Lead sponsor | Hadassah Medical Organization, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hematological Malignancy, Neoplasm Metastasis |
| Intervention type | Procedure |
| Interventions | DLI sensitized against antigens expressed by the host. |
| Enrollment | 50 |
| Start date | Aug 1, 2001 |
| First posted | Sep 8, 2005 |
| Last update posted | Apr 8, 2011 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: